相关实验视频
Updated: Jul 12, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.4K
超出阿尔茨海默氏症疾病之外的粉样β和陶蛋白
Morteza Abyadeh1, Vivek Gupta2, Joao A Paulo3
1ProGene Technologies Pty Ltd., Sydney, NSW, Australia.
Neural regeneration research
|October 31, 2023
概括
粉样β和蛋白聚合是阿尔茨海默病的关键. 这些蛋白质的异常形式与许多其他神经,视网膜,心血管和全身疾病有关,突出显示了它们广泛的病理影响.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 粉样β和陶蛋白在生理上存在,但在病理上聚集.
- 蛋白质聚合是阿尔茨海默氏症病原的标志.
- 异常蛋白质行为与各种神经退行性和系统性疾病有关.
研究的目的:
- 审查粉样β和蛋白之间的联系.
- 探索它们在阿尔茨海默氏症以外的一系列疾病中的作用.
- 为了提供一个全面的概述蛋白质聚合在疾病.
主要方法:
- 最近研究的文献综述.
- 对病理机制的分析.
- 综合了有关蛋白质聚合和疾病的发现.
主要成果:
- 粉样β和tau聚合是阿尔茨海默病的核心.
- 这些蛋白质与帕金森病,ALS,玻璃眼和AMD有关.
- 已经确立了与心血管疾病,癌症,TBI和糖尿病的联系.
结论:
- 粉样β和蛋白的失调超出了阿尔茨海默氏症的范围.
- 异常的蛋白质聚合是各种病理中常见的机制.
- 对于更广泛的治疗策略,对这些蛋白质病变的进一步研究是有必要的.
相关概念视频
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200

